Skip to main content
Ophélia Maertens on Muck Rack

Ophélia Maertens

As seen in: Cell Press, Cancer Discovery
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ophélia

Contact Ophélia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers

|
By Stephanie L. Guerra, Ophélia Maertens, Ryan Kuzmickas, Thomas De Raedt
| Cell Press Verified
Highlights • Combined MEK/BET inhibitors are effective in KRAS-mutant NSCLCs • Sensitivity is dependent on HOXC10, which is overexpressed in 51% of tumors • Aberrant HOXC10 expression is largely caused by defects in PRC2 genes • MEK/BET inhibitors co-suppress Ras output and HOXC10 to cause replication defects Summary While KRAS mutations are common in non-small cell lung cancer (NSCLC), effective treatments are lacking.
Open in Who Shared Issue with article?

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas

|
By Ophélia Maertens, Ryan Kuzmickas, Haley E. Manchester, Chloe E. Emerson
| Cancer Discovery Verified
Research Articles Ophélia Maertens, Ryan Kuzmickas, Haley E. Manchester, Chloe E. Emerson, Alessandra G. Gavin, Caroline J. Guild, Terence C. Wong, Thomas De Raedt, Christian Bowman-Colin, Elodie Hatchi, Levi A. Garraway, Keith T. Flaherty, Shailja Pathania, Stephen J. Elledge and Karen Cichowski DOI: 10.1158/2159-8290.CD-18-0879 Published April 2019 Abstract Although the majority of BRAF-mutant melanomas respond to BRAF/MEK inhibitors, these agents are not typically curative.
Open in Who Shared Issue with article?

MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF, NRAS, and NF1 mutant melanomas

|
By Ophélia Maertens, Haley E. Manchester, Ryan Kuzmickas, Chloe E. Emerson
| Cancer Discovery Verified
Research Articles Ophelia Maertens, Ryan Kuzmickas, Haley E Manchester, Chloe E. Emerson, Alessandra G Gavin, Caroline J Guild, Terence C Wong, Thomas De Raedt, Christian Bowman-Colin, Elodie Hatchi, Levi A. Garraway, Keith T Flaherty, Shailja Pathania, Stephen J. Elledge and Karen Cichowski DOI: 10.1158/2159-8290.CD-18-0879 Abstract While the majority of BRAF-mutant melanomas respond to BRAF/MEK inhibitors, these agents are not typically curative.
Open in Who Shared Issue with article?
See all 4 articles